A detailed history of Weaver Consulting Group transactions in Eli Lilly & CO stock. As of the latest transaction made, Weaver Consulting Group holds 591 shares of LLY stock, worth $545,912. This represents 0.2% of its overall portfolio holdings.

Number of Shares
591
Previous 611 3.27%
Holding current value
$545,912
Previous $475,000 12.63%
% of portfolio
0.2%
Previous 0.19%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024

SELL
$724.87 - $909.04 $14,497 - $18,180
-20 Reduced 3.27%
591 $535,000
Q1 2024

Apr 16, 2024

BUY
$592.2 - $792.28 $2,961 - $3,961
5 Added 0.83%
611 $475,000
Q4 2023

Jan 22, 2024

BUY
$525.19 - $619.13 $5,251 - $6,191
10 Added 1.68%
606 $353,000
Q3 2023

Oct 13, 2023

SELL
$434.7 - $599.3 $56,511 - $77,909
-130 Reduced 17.91%
596 $320,000
Q2 2023

Jul 19, 2023

BUY
$350.74 - $468.98 $18,589 - $24,855
53 Added 7.88%
726 $340,000
Q1 2023

Apr 11, 2023

BUY
$310.63 - $364.82 $1,242 - $1,459
4 Added 0.6%
673 $231,000
Q3 2022

Oct 04, 2022

BUY
$296.48 - $337.87 $1,482 - $1,689
5 Added 0.75%
669 $216,000
Q2 2022

Jul 20, 2022

SELL
$278.73 - $327.27 $20,904 - $24,545
-75 Reduced 10.15%
664 $215,000
Q4 2021

Feb 01, 2022

BUY
$224.85 - $279.04 $166,164 - $206,210
739 New
739 $204,000
Q4 2020

Jan 29, 2021

SELL
$130.46 - $172.63 $83,494 - $110,483
-640 Closed
0 $0
Q2 2020

Jul 24, 2020

BUY
$136.42 - $164.18 $1,227 - $1,477
9 Added 1.43%
640 $105,000
Q1 2019

Jun 19, 2019

BUY
$111.31 - $131.02 $70,236 - $82,673
631 New
631 $72,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $878B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Weaver Consulting Group Portfolio

Follow Weaver Consulting Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weaver Consulting Group, based on Form 13F filings with the SEC.

News

Stay updated on Weaver Consulting Group with notifications on news.